DK1210430T3 - MUC-1-afledte peptider - Google Patents

MUC-1-afledte peptider

Info

Publication number
DK1210430T3
DK1210430T3 DK00965943T DK00965943T DK1210430T3 DK 1210430 T3 DK1210430 T3 DK 1210430T3 DK 00965943 T DK00965943 T DK 00965943T DK 00965943 T DK00965943 T DK 00965943T DK 1210430 T3 DK1210430 T3 DK 1210430T3
Authority
DK
Denmark
Prior art keywords
muc
polypeptides
peptides
derived peptides
derived
Prior art date
Application number
DK00965943T
Other languages
Danish (da)
English (en)
Inventor
Rienk Offringa
Bruce Acres
Lukas Carl Heukamp
Cornelis Johanna Maria Melief
Joyce Taylor-Papadimitriou
Mireille Thomas
Original Assignee
Transgene Sa
Imp Cancer Res Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9921242.5A external-priority patent/GB9921242D0/en
Application filed by Transgene Sa, Imp Cancer Res Tech filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1210430T3 publication Critical patent/DK1210430T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK00965943T 1999-09-08 2000-09-07 MUC-1-afledte peptider DK1210430T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9921242.5A GB9921242D0 (en) 1999-09-08 1999-09-08 Cancer vaccine and diagnosis
EP99402237 1999-09-10
US18721500P 2000-03-03 2000-03-03

Publications (1)

Publication Number Publication Date
DK1210430T3 true DK1210430T3 (da) 2006-11-20

Family

ID=27240232

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00965943T DK1210430T3 (da) 1999-09-08 2000-09-07 MUC-1-afledte peptider

Country Status (11)

Country Link
US (3) US20050142640A1 (fr)
EP (1) EP1210430B1 (fr)
JP (1) JP2003510094A (fr)
AT (1) ATE338121T1 (fr)
AU (1) AU778701B2 (fr)
CA (1) CA2383737C (fr)
DE (1) DE60030450T2 (fr)
DK (1) DK1210430T3 (fr)
ES (1) ES2270870T3 (fr)
PT (1) PT1210430E (fr)
WO (1) WO2001018035A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090004212A1 (en) * 1997-12-30 2009-01-01 Franz-Georg Hanisch Tumour vaccines for MUC1-positive carcinomas
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
EP1531842A4 (fr) 2000-12-22 2007-03-07 Dana Farber Cancer Inst Inc Regulation de la proliferation cellulaire par muc1
JP2004533421A (ja) 2001-03-27 2004-11-04 バイオミラ，インコーポレイテッド Ｔ１免疫応答とｔ２免疫応答との間で調節するためのワクチン
CN101024842A (zh) 2001-11-07 2007-08-29 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
WO2003089451A2 (fr) * 2002-04-22 2003-10-30 Dyax Corporation Anticorps specifiques du polypeptide de mucine
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
GB0321614D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Vaccines
WO2005042573A1 (fr) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation de l'interaction de muc1 avec des ligands de muc1
EP1697399B1 (fr) * 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS Epitope de lymphocyte t cytotoxique humain et son epitope agoniste issus du nombre non variable de sequences repetees en tandem de muc-1
TWI395591B (zh) 2004-04-01 2013-05-11 Oncothyreon Inc 黏液性糖蛋白（ｍｕｃ-１）疫苗
US8871250B2 (en) 2005-06-28 2014-10-28 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine
US20090317414A1 (en) * 2006-07-25 2009-12-24 4G Vaccines Pty Ltd Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
WO2008035350A1 (fr) * 2006-09-21 2008-03-27 Vaxil Biotherapeutics Ltd. Vaccins à multiples épitopes spécifiques à un antigène
WO2008097844A2 (fr) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Méthodes et compositions associées à la régulation de l'apoptose par des protéines muc1 et des protéines pro-apoptotiques contenant seulement le domaine bh3
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
WO2009108807A1 (fr) * 2008-02-26 2009-09-03 The Regents Of The University Of California Glycopeptides et procédés pour les préparer et les utiliser
US8524669B2 (en) 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
AU2010253834B2 (en) * 2009-05-27 2013-12-19 Dana-Farber Cancer Institute, Inc. Inhibition 0f inflammation using antagonists of MUC1
WO2011100688A1 (fr) 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Antagonistes améliorés du muc1
EP2374470A1 (fr) 2010-04-08 2011-10-12 Beta Innov Utilisation thérapeutique de la protéine Beta2m
BR112012028893A2 (pt) 2010-05-10 2017-12-12 Ascend Biopharmaceuticals Pty Ltd composições imunoestimuladoras e de vacina
EP2678005A4 (fr) 2011-02-24 2015-06-10 Oncothyreon Inc Vaccin glycolipopeptidique à base de muc1 comportant un adjuvant
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof
EP2800762B1 (fr) * 2012-01-03 2018-01-03 The United States of America, as represented by the Secretary, Department of Health and Human Services Épitopes de ctl endogènes et agonistes de l'antigène tumoral muc1
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
EP3269726B1 (fr) * 2015-03-09 2025-05-07 Nec Corporation Peptide dérivé de muc1, composition pharmaceutique pour le traitement ou la prévention du cancer à l'aide de celui-ci, inducteur de la réponse immunitaire, et procédé de production de cellules présentatrices d'antigènes
WO2018187515A1 (fr) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Vaccins à base de peptides, procédés de fabrication et utilisations de ceux-ci pour induire une réponse immunitaire
EP3903811A1 (fr) * 2020-05-01 2021-11-03 R.G.C.C. Holdings AG Composition pharmaceutique et procédé pour induire une réponse immunitaire

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
CA2003211A1 (fr) * 1988-11-17 1990-05-17 Pei-Xiang Xing Anticorps monoclonaux
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
ES2139012T3 (es) * 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
IL110464A0 (en) 1994-07-26 1994-10-21 Univ Ramot Novel proteins for the diagnosis, imaging, and therapy of human cancer
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6024965A (en) 1996-10-18 2000-02-15 Erasums University Rotterdam Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection
CA2289742C (fr) * 1997-05-08 2013-07-16 Biomira Inc. Procede de generation de cellules t activees et de cellules de presentation d'antigene et a impulsion antigenique
JP2002505318A (ja) * 1998-03-05 2002-02-19 アゴーロン・ファーマシューティカルズ・インコーポレイテッド 非ペプチドＧｎＲＨ因子
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies

Also Published As

Publication number Publication date
WO2001018035A3 (fr) 2001-11-08
WO2001018035A9 (fr) 2002-09-06
US20050142640A1 (en) 2005-06-30
AU7651500A (en) 2001-04-10
EP1210430A2 (fr) 2002-06-05
DE60030450T2 (de) 2007-08-30
DE60030450D1 (de) 2006-10-12
CA2383737C (fr) 2011-01-18
US7892828B2 (en) 2011-02-22
ES2270870T3 (es) 2007-04-16
US20080227082A1 (en) 2008-09-18
US20100255501A1 (en) 2010-10-07
PT1210430E (pt) 2006-12-29
ATE338121T1 (de) 2006-09-15
WO2001018035A2 (fr) 2001-03-15
JP2003510094A (ja) 2003-03-18
CA2383737A1 (fr) 2001-03-15
EP1210430B1 (fr) 2006-08-30
AU778701B2 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
DK1210430T3 (da) MUC-1-afledte peptider
NZ511454A (en) Immunotherapeutic methods using epitopes of WT-1 and GATA-1 for the treatment of cancers including leukaemia
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
NL300013I1 (nl) Nieuwe protein met TNF-remmende werking en hun ber
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
PT920510E (pt) Quimeras de gnrh-leucotoxina
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
ATE368053T1 (de) Antimikrobielle peptide
DE69320967D1 (de) Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
Bownds et al. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2. 1 binding affinity and stability in solution
GB9219936D0 (en) Vaccines
DK0996726T3 (da) T-celle-membranprotein (TIRC7), peptider og antistoffer afledt deraf og anvendelse deraf
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
BR0312889A (pt) Polipeptìdeo t20 peguilado
DE60118359D1 (de) Humanische pellino-polypeptide
FI953093A0 (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
ATE362939T1 (de) Dimere von thrombinpeptidderivaten
WO2001029220A3 (fr) Peptides antigeniques mage-a12 et utilisation
DK1095143T3 (da) Inhibitor til diagnosticering og behandling af patienter med hæmofili A
PT773999E (pt) Receptor orfao or-1 pertencente a familia de receptores nucleares
WO2001011937A3 (fr) Utilisation de la colostrinine, de ses peptides constitutifs et de ses analogues pour activer des cytokines
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
DK0616642T3 (da) Hidtil ukendte thrombininhibitoriske proteiner fra landblodigler
DK0646016T3 (da) Syntetiske peptider til behandlling af myasthenia gravis
ATE281524T1 (de) Moraxella catarrhalis pilq proteine